Therapy News and Research

RSS

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Statewide Initiative to increase sudden cardiac arrest survival rates launched in Minnesota

Medtronic Foundation and Take Heart Minnesota™ today announced a comprehensive statewide initiative, the first in the nation, designed to increase sudden cardiac arrest (SCA) survival rates. SCA is a condition in which the heart abruptly stops without warning. More than 4,500 cases of SCA were reported in Minnesota in 2008, an average of 12.5 incidences per day.

21 Oct 2009

Palmerolide A: Real hope for cancer treatment

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

21 Oct 2009

Broadlane's partnership with CTC helps to deliver 24% average savings to its clients

Broadlane has delivered an average savings of 24 percent to healthcare clients by partnering with Compression Therapy Concepts (CTC), a certified, small-business, woman-owned diversity supplier of Deep Vein Thrombosis (DVT) prevention products. The relationship has also increased CTC’s market share within the Broadlane client base from less than 1 percent to approximately 60 percent.

21 Oct 2009

Book reviews applications of genetic research in the fields of exercise science and sports medicine

This publication reviews past, current and future applications of genetic research in the fields of exercise science and sports medicine. It highlights ethical concerns, potential clinical applications and exploitation of genetic information. The authors, an interdisciplinary group of experts comprising clinicians, exercise scientists, human geneticists and other biological scientists, present an integrated and holistic understanding of the field to the reader.

21 Oct 2009

Findings suggest a new approach to the rehabilitation of stroke patients

What's new: Researchers at MIT and San Camillo Hospital in Venice, Italy, have shown that motor impairments in stroke patients can be understood as impairments in specific combinations of muscle activity, known as synergies.

21 Oct 2009

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

St. Jude Medical, Inc. today announced it has received European CE Mark approval for the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds). The quadripolar system offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

CCS is the largest funder of childhood and adolescent cancer research in the charitable sector

A new report released today by the Canadian Cancer Research Alliance reveals that the Canadian Cancer Society (CCS) is the largest funder of childhood and adolescent cancer research in the charitable sector, contributing 23 per cent of total funding. The B.C. and Yukon division of the CCS contributes more than 40 per cent of that funding through donations from Cops for Cancer.

21 Oct 2009

Practical changes in school infrastructure can provide better environments for disabled students

NJIT Research Architect B. Lynn Hutchings believes that by making a few practical, effective and relatively inexpensive changes to school buildings, they can become better environments for students with severe physical, intellectual, and sensory disabilities.

21 Oct 2009

Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide* afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

21 Oct 2009

Osteologix to continue clinical development of NB S101 osteoporosis drug

Osteologix, Inc., a bio-pharmaceutical company announced today that the company will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the United States and the rest of the world markets. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

StemCells, Inc. announced today new preclinical data showing that its human neural stem cells protect cone photoreceptors (cones) in the eye from progressive degeneration and preserve visual function long term.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

Therapy News and Research

Oxygen Biotherapeutics announces its expanded product development plan

New tools needed to identify men and women at risk for the most aggressive cancers

Statewide Initiative to increase sudden cardiac arrest survival rates launched in Minnesota

Palmerolide A: Real hope for cancer treatment

Broadlane's partnership with CTC helps to deliver 24% average savings to its clients

Book reviews applications of genetic research in the fields of exercise science and sports medicine

Findings suggest a new approach to the rehabilitation of stroke patients

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

CCS is the largest funder of childhood and adolescent cancer research in the charitable sector

Practical changes in school infrastructure can provide better environments for disabled students

Cook Medical launches new products for treating peripheral arterial disease

Osteologix to continue clinical development of NB S101 osteoporosis drug

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Positive results from KAI Pharmaceuticals' pain therapeutic program

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Targacept presents data from Phase 2b clinical trial of TC-5214

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

NCCN Guidelines for Acute Myeloid Leukemia updated

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News